You are here: Home > Results > Grants Funded

Grants Funded

Since 2008, support from Good Cookies like YOU has helped Cookies for Kids' Cancer fund nearly 6 DOZEN childhood cancer research grants, leading to 27 promising new treatments and clinical trials available to children fighting cancer TODAY.

Cookies for Kids' Cancer is committed to funding promising research for less toxic therapies for children battling cancer. Each year grants are given under the guidance of the Medical Advisory Board. The mission of the organization is to fund as much promising research as possible, while keeping administrative costs as low as possible. With 7 full years as a non-profit complete, Cookies for Kids' Cancer is now eligible for review by Charity Navigator. If you have questions about how Cookies for Kids' Cancer makes grants or allocates funds, please email emily@cookiesforkidscancer.org.

Treatments Now in Clinical Trial:

Memorial Sloan-Kettering Cancer Center

HU3F8 antibody treatment

Saponin adjuvant for GD2 conjugate vaccine

Convection-enhanced delivery of 124I-8H9 Brainstem glioma

Children's Hospital of Philadelphia

Engineered t cell therapy - recurrent neuroblastoma & b cell malignancies

Phase I trial of MK1775, approved and activated for accrual

Texas Children's Cancer Center

Phase I/II trials of ABT-888 plus XRT - pediatric brain tumors

Immunotherapy with dual-specific NKT cells - Neuroblastoma

St. Jude Children's Research Hospital

CD-20 targeted therapy - Leukemia

Anti-GD2 monoclonal antibody therapy - Neuroblastoma

Dana-Farber Cancer Institute

Targeting of Cdk4 signaling in pediatric Rhabdoid tumors

Phase II study of clofarabine in refractory Langerhans cell histiocytosis


As of 2013, a portion of funds raised are also used to MATCH, dollar for dollar, the federal allowance per child enrolled in the Children's Oncology Group's Phase I & Pilot Consortium.

COG Phase 1/Pilot Consortium Studies:

A Phase 1 Dose Escalation Study of Seneca Valley Virus (NTX-010), a Replication-Competent Picornavirus, in Pediatric Patients with Recurrent/Refractory Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors with Neuroendocrine Features

A Phase 1/2 Study of PF-02341066, an Oral Small Molecule Inhibitor of Anaplastic Lymphoma Kinase (ALK) and C-Met, in Children with Relapsed/Refractory Solid Tumors and Anaplastic Large Cell Lymphoma

A Phase 1 Study of Temsirolimus in Combination with Irinotecan and Temozolomide in Children, Adolescents, and Young Adults with Relapsed or Refractory Solid Tumors

A Phase 1 Study of JAK Inhibition (Ruxolitinib) in Children with Relapsed or Refractory Solid Tumors, Leukemias, and Myeloproliferative Neoplasms

A Phase I Dose Escalation Study of REOLYSIN, a Replication Competent Reovirus, in Pediatric Patients with Relapsed or Refractory Solid Tumors

A Phase 1 Study of the c-Met Inhibitor, Tivantinib (ARQ 197, IND#112603) in Children with Relapsed or Refractory Solid Tumors

A Phase 1 Study of Imetelstat, a Telomerase Inhibitor, in Children with Refractory or Recurrent Solid Tumors and Lymphoma

A Phase 1 Study of Temsirolimus (CCI-779, IND#61010) in Combination with Intensive Re-Induction Therapy for Children with Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkin Lymphoma

A Phase 1 study of AMG 386 (trebananib, IND#114215), an Angiopoietin Neutralizing Peptibody, in Children with Relapsed or Refractory Solid Tumors, including CNS Tumors.

A Phase 1 study of XL184 (Cabozantinib, IND# 116059) in Children and Adolescents with Recurrent or Refractory Solid Tumors, including CNS Tumors

A Phase 1 Study of Crizotinib (IND# 105573) in Combination with Conventional Chemotherapy for Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma

A Phase 1 study of the TEM-1 antibody, MORAb-004 (IND# 103821), in Children with Recurrent or Refractory Solid Tumors

A Phase 1 Study of AZD1775 (MK-1775, IND#116459) Concurrent with Local Radiation Therapy for the Treatment of Newly Diagnosed Children with Diffuse Intrinsic Pontine Gliomas

A Phase 1/2 Study of MK-1775 (AZD1775, IND# 121422) in Combination with Oral Irinotecan in Children, Adolescents, and Young Adults with Relapsed or Refractory Solid Tumors

A Phase 1/2 Study of BMN 673 (IND #121510), an Oral Poly(ADP-ribose) Polymerase Inhibitor, Plus Temozolomide in Children with Refractory or Recurrent Malignancies

A Phase 1/2 Trial of Brentuximab Vedotin (SGN35, IND#117117) in Combination with Gemcitabine for Pediatric and Young Adult Patients with Relapsed or Refractory Hodgkin Lymphoma


Research Grants Funded to Date:

AMOUNT CENTER RESEARCHER GRANT

2014

$100,000

Children's Hospital of Philadelphia

Dr. Maris

Identifying novel drug combinations for neuroblastoma

$100,000

Children's Hospital of Philadelphia

Dr. Aplenc

Chimeric antigen receptor T cell immunotherapy for pediatric acute myeloid leukemia

$150,000*

Children's Oncology Group

Dr. LaQuaglia

Comprehensive national study to standardize treatments after pulmonary metastectomy in patients with newly diagnosed or recurrent osteosarcoma and pulmonary metastasis. *Second year of 3-year project totaling $450,000.

$100,000

Dana-Farber Cancer Institute

Dr. Dranoff

A Phase I Study of irradiated GM-CSF secreting autologous neuroblastoma cell vaccine (GVAX) for relapsed or refractory neuroblastoma

$200,000

Memorial Sloan Kettering Cancer Center

Dr. Modak

Targeting pediatric solid tumors: A pilot study of Radiolmmuno-PET imaging using 124I-Humanized 3F8

$100,000

Memorial Sloan Kettering Cancer Center

Dr. Kushner

Bivalent vaccine plus beta-glucan for high-risk neuroblastoma in first remission

$100,000

St. Jude Children's Research Hospital

Dr. Mullighan

Identifying novel drivers and childhood acute lymphoblastic leukemia disease and resistance

$100,000

Texas Children's Cancer Center

Dr. Zage

A Phase I Study of vandetanib (CaprelsaTM) in combination with 13-cis-retinoic acid in children with relapsed or refractory solid tumors

$100,000

Texas Children's Cancer Center

Dr. Gottschalk

IL13Ra2-CAR T-cell therapy for pediatric high grade glioma

2013

$100,000

Children's Hospital Of Philadelphia

Dr. Nichols

Novel cell-based therapy for b cell leukemias and lymphomas

$100,000

Children's Hospital Of Philadelphia

Dr. Thomas-Tikhonenko

Decreasing resistance to chemotherapies in pediatric lymphomas, and decreasing sensitivities and effects related to the chemotherapy drug Doxorubicin

$350,000

Children's Oncology Group

Matching federal funds per child enrolled in Phase I clinical trials

$150,000*

Children's Oncology Group

Dr. LaQuaglia

Comprehensive national study to standardize treatments after pulmonary metastectomy in patients with newly diagnosed or recurrent osteosarcoma and pulmonary metastasis. *First year of 3-year project totaling $450,000.

$100,000

Dana-Farber Cancer Institute

Dr. Stegmaier

New treatments for neuroblastoma by targeting the Epigenome

$100,000

Memorial Sloan-Kettering Cancer Center

Dr. Cheung

Retargeting t cells using bispecific antibody against receptor Tyrosine Kinase-like orphan receptors 2 (Ror2) in solid tumors

$100,000

St. Jude Children's Research Hospital

Dr. Inaba

Genetic characterization and therapeutic targeting of pediatric mixed phenotype acute leukemia

$100,000

Texas Children's Cancer Center

Dr. Berg

Phase I trial of Sgt-53, a novel nanoparticle therapy, for children with refractory or recurrent solid tumors

$100,000

Texas Children's Cancer Center

Dr. Metelitsa

Phase I clinical trial of a novel immune therapy using dual-specific Nkt cells for children with neuroblastoma

2012

$350,000

Children's Oncology Group

Matching federal funds per child enrolled in Phase I clinical trials

$100,000

Children's Hospital Of Philadelphia

Dr. Attiyeh

Xpo1 Inhibition in neuroblastoma

$100,000

Children's Hospital Of Philadelphia

Dr. Bassing

Targeting Bcl11b Haploin sufficient lymphoid tumors 6

$100,000

Dana-Farber Cancer Institute

Dr. Roberts

Targeting of Cdk4 signaling in pediatric Rhabdoid tumors

$100,000

Dana-Farber Cancer Institute

Dr. Galiando

Phase II study of clofarabine in refractory Langerhans cell histiocytosis

$100,000

Dana-Farber Cancer Institute

Dr. Shusterman

Csf producing whole tumor vaccine for neurblastoma

$100,000

Memorial Sloan-Kettering Cancer Center

Dr. Cheung

Dual specific human monoclonal antibody targeting IGF-I and IGF-II for pediatric cancers

$100,000

Memorial Sloan-Kettering Cancer Center

Dr. Kramer

Delivery of 124-I-8h9 non-progressive diffuse Pontine Gliomas.

$100,000

St. Jude Children's Research Hospital

Dr. Furman

Hu14.18322a + Multi-Modality treatment for neuroblastoma

$100,000

Texas Children's Cancer Center

Dr. Gottschalk

Fap-targeted t cell therapy for osteosarcoma

2011

$100,000

St. Jude Children's Research Hospital

Dr. Gilbertson

Rapid and accurate diagnosis of Medolloblastoma subtypes in trials

$100,000

Children's Hospital Of Philadelphia

Dr. Maris

Molecular oncology for pediatric cancers

$100,000

Children's Hospital Of Philadelphia

Dr. Weiss

Modeling juvenile myelomonocytic Leukemia patient Ips cells

$100,000

Dana-Farber Cancer Institute

Dr. Stegmaier

Validation of fak therapeutic target in Ewings Sarcoma

$100,000

Dana-Farber Cancer Institute

Dr. George

Development of dendritic call vaccine against Alk-Positive

$100,000

Memorial Sloan-Kettering Cancer Center

Dr. Cheung

A safe, potent Saponin adjuvant for Gd2 conjugated vaccine for neuroblastoma

$100,000

Memorial Sloan-Kettering Cancer Center

Dr. LaQuaglia

Phase I trial of Hepatic Artery Infusion/neuroblastoma tumors in the liver

$100,000

Memorial Sloan-Kettering Cancer Center

Dr. Cheung

Bite Therapy

$100,000

Memorial Sloan-Kettering Cancer Center

Dr. Cheung

Bite Therapy

$100,000

Texas Children's Cancer Center

Dr. Metelitsa

Immunotherapy of neuroblastoma with dual-specific Nkt cells

$100,000

Texas Children's Cancer Center

Dr. Nuchtern

Genomic anatomy of chemotherapy-resistant neuroblastoma

2010

$100,000

Children's Hospital Of Philadelphia

Dr. Grupp

Engineered T Cell Therapy For Recurrent Neuroblastoma & B Cell Malignancies

$100,000

Children's Hospital Of Philadelphia

Dr. Hogarty

Sirna based Kimome screen to id Mcl1 antagonists for resistant Tumors

$100,000

Memorial Sloan-Kettering Cancer Center

Dr. Cheung

Bite Therapy, 2nd round of funding

$100,000

St Jude Children's Research Hospital

Dr. Bhojwani

CD-20 targeted immunotherapy for relapsed childhood neuroblastoma

$100,000

Texas Children's Cancer Center

Dr. Shohet

Therapy for relapsed neuroblastoma. P13k/Aktm tor pathway inhibition

$100,000

Texas Children's Cancer Center

Dr. Su

Therapy efficacy study for newly diagnosed brainstem gliomas

2009

$100,000

Memorial Sloan-Kettering Cancer Center

Dr. Cheung

Bite Therapy

$35,000

Texas Children's Cancer Center

Dr. Rabin

Novel therapy using JAK-STAT pathway inhibitors in childhood leukemias

$50,000

Texas Children's Cancer Center

Dr. Louis

A phase I/II study using allogenic tumor cell vaccination with oral metronomic cytoxan in patients with high-risk neuroblastoma

$150,000

Texas Children's Cancer Center

Two Grants

2008

$400,000

Memorial Sloan-Kettering Cancer Center

Dr. Cheung

Hu3f8 antibody treatment for neuroblastoma